MetaVia Stock
MetaVia Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Hyung Heon Kim
- Employees
- 8
- Market cap
- $8 M
- IPO
- 05/08/2016
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is…
MetaVia stock: price history
1D
-8.0%
1W
-10.6%
1M
-18.2%
6M
-10.0%
YTD
-85.0%
1Y
-89.0%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~2% stronger price swings than usual
Ask the agents about MetaVia
Analyst assessment of MetaVia
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 10/07/2026
MetaVia stock metrics
P/E
-0.31
P/B
1.1
EV/EBITDA
0.29
RETURN ON EQUITY
-77.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
72.9%
FLOAT SHARES
4,804,307
AVG. DAILY VOLUME (30D)
82,488
Insider transactions (SEC)
Browne Sarah Kaplan
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about MetaVia stock
What does MetaVia do?
MetaVia Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Hyung Heon Kim, the company employs around 8 people.
The IPO was on 05/08/2016; the stock trades on NASDAQ under the ticker MTVA.
What do analysts say about MetaVia stock?
2 analysts rate the stock, the consensus is Buy (as of 10/07/2026).
This is an external assessment, not a statement by Market Jury.
When does MetaVia report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 2% stronger than usual.
Does MetaVia pay a dividend?
No, MetaVia currently does not pay a dividend.
Which stocks are comparable to MetaVia?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get MetaVia stock analyzed?
Clicking "Analyze stock" lets five strategies assess MetaVia against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.